Enrolling by invitationPhase 2NCT06674577

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

Studying IgA Nephropathy

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Vera Therapeutics, Inc.
Principal Investigator
Zeeshan Khawaja, MD
Vice President, Clinical Development
Intervention
Atacicept 150 mg(drug)
Enrollment
476 enrolled
Eligibility
18-99 years · All sexes
Timeline
2024 – 2028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06674577 on ClinicalTrials.gov

Other trials for IgA Nephropathy

Additional recruiting or active studies for the same condition.

See all trials for IgA Nephropathy →

← Back to all trials